Answers are grounded in this paper and cite their sources.
A DNA vaccine expressing conserved elements (CEs) of the SIV capsid (p27Gag) was designed to induce broad immune responses that can target diverse viral variants, limit immune escape and control viral rebound in the absence of antiretroviral therapy (ART). SIV-infected rhesus macaques receiving ART were primed with multiple doses of this vaccine co-formulated with a second plasmid expressing the genetic adjuvant, E. coli heat-labile enterotoxin (LT), via gene gun. During ART, virological suppression was highly variable across animals, with most macaques maintaining detectable viremia throughout the vaccination period. Following a boost consisting of a co-delivery of the adjuvanted CE DNA vaccine with a full-length (FL) SIV p57gag DNA vaccine, CE-primed macaques developed significantly higher CE-specific cellular and humoral immune responses than macaques immunized at each dose only with the full-length (FL) SIV p57gag DNA vaccine or mock-vaccinated controls. However, CE-specific responses were lower in macaques that had higher frequencies of myeloid-derived suppressor cells (MDSCs) and T cells expressing exhaustion markers. Upon ART interruption, all macaques exhibited a wide range in viral rebound and overall, there were no differences in mean viral loads or the time to viral rebound between the vaccinated and control groups. Notably, post-ART, the T cell repertoire shifted from CEs toward more variable sequences that were induced by the initial viral infection. These results suggest that ongoing viral replication during incomplete ART suppression, pre-existing virus-induced immune responses and persistent immune dysfunction can interfere with the immunogenicity and efficacy of a therapeutic vaccine designed to induce responses against conserved viral antigens.
No takes yet. Share an insight, caveat, or question.
Munson et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: